Generare Secures €20M Series A to Unlock Cryptic Molecular Chemistry from Microbial Genomes
核心洞察
Paris-based Generare (搜索) raised €20 million in Series A funding to expand its platform that decodes microbial genomes (搜索) to discover previously inaccessible small molecules for drug discovery.
The company discovered more than 200 novel molecules in 2025 alone, outpacing all other players in the field combined who found only a few dozen new compounds.
Generare (搜索) aims to scale its molecular library tenfold by 2027 to over 2,000 molecules, targeting the estimated 97% of genomic data buried in unexplored microbial genomes (搜索).
Paris-based biotechnology company Generare (搜索) has secured €20 million in Series A funding to advance its platform that unlocks previously inaccessible molecular chemistry from microbial genomes (搜索). The round was co-led by Alven (搜索) and Daphni (搜索), with participation from existing investors including Galion.exe (搜索), Teampact Ventures (搜索) and Vives Partners (搜索).
Founded in 2023, Generare (搜索) is positioning itself at the intersection of synthetic biology and artificial intelligence by addressing what the company identifies as a fundamental bottleneck in drug discovery: the lack of genuinely novel molecular data. The company's approach focuses on expanding the underlying chemical universe rather than developing more sophisticated algorithms.
Addressing the Data Constraint in AI Drug Discovery
While much of the excitement in AI-driven drug discovery has centered on increasingly sophisticated computational models, Generare (搜索) is taking a different approach based on the premise that current systems are limited not by computational power, but by the narrowness of the chemical data they are trained on.
"Drug discovery has a data problem. The entire field trains its models on the same recycled chemistry and expects different outcomes," said co-founder and Chief Executive Guillaume Vandenesch. "The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data and we're solving that by building the largest proprietary dataset of cryptic small molecules."
The company's platform decodes microbial genomes (搜索) to uncover previously inaccessible "cryptic" chemistry—small molecules shaped by billions of years of evolution. Using high-throughput cloning, sequencing and expression technologies, Generare (搜索) identifies gene clusters likely to produce bioactive compounds and characterizes them for structure and biological activity.
Unprecedented Discovery Output
In 2025 alone, Generare (搜索) identified more than 200 novel molecules, significantly outpacing the rest of the field combined, which discovered only a few dozen new compounds. These compounds are already being explored by research partners as potential starting points for new therapeutics.
Generare (搜索) estimates that approximately 97% of the genomic data available to humanity remains buried in microbial genomes (搜索), unread. The company is generating value from this missing data, providing it at quality and scale to address what it sees as a decades-long constraint in pharmaceutical research.
Historical Success of Microbial-Derived Drugs
Microbial genomes (搜索) have proven to be a rich source for drug discovery. Examples of successful drugs derived from microbes include Lugdunin (搜索), an antibiotic taken from a bacterium found in the human nose; Taromycin A/B (搜索), discovered in the Actinobacteria genome and capable of fighting Methicillin-resistant Staphylococcus aureus (搜索); and Vidarabine, an antiviral drug derived from a marine sponge-associated fungus.
The company specializes in small molecules, a class of chemistry that underlies many of the best-known medicines currently in use.
Scaling Ambitions and Market Positioning
The proceeds from the Series A round will be used to scale the company's proprietary dataset of small molecules and expand its platform capabilities. Generare (搜索) aims to increase its discovery output tenfold by 2027, targeting more than 2,000 molecules with an ultimate goal of exceeding 10,000 over time. The company also plans to double its current team of 25 computational biologists, chemists, synthetic biologists, technicians and engineers.
Dr. Vincent Libis, CSO and Co-Founder at Generare (搜索), emphasized the company's strategic focus: "Nature has been the #1 source of innovative modes of action for drugs and we've only scratched the surface of its potential. We're building the infrastructure to change that with the largest commercial library of evolution-derived molecules in the world, a dataset that improves with every cycle, and a platform that can supply companies with genuinely new starting points for drug discovery."
Differentiated Approach in Competitive Landscape
Generare (搜索)'s strategy reflects a broader shift within the European techbio ecosystem. While companies such as Exscientia, BenevolentAI and Owkin (搜索) have built their platforms around machine learning models applied to existing biomedical data, and others like Recursion Pharmaceuticals are generating large-scale phenotypic datasets to feed AI systems, Generare is focused on expanding the underlying chemical universe itself.
This positioning has begun to attract attention from pharmaceutical and agrochemical companies, which are increasingly seeking access to differentiated datasets as a competitive advantage. The company's emphasis on evolution-derived molecules offers a complementary approach to AI-first players, effectively aiming to supply the "fuel" for the next generation of algorithms.
The convergence of biology, computation and engineering continues to accelerate across Europe, with venture capital flowing into techbio platforms that combine wet-lab capabilities with scalable data generation. The emergence of specialized datasets—whether genomic, phenotypic or chemical—is becoming a defining feature of the sector, with Generare (搜索)'s focus on unlocking the vast reservoir of natural products encoded in microbial genomes (搜索) representing a strategic bet that the next wave of drug discovery will be driven not just by smarter algorithms, but by access to biology that has remained out of reach.